0.00Open0.00Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover1132.77%IV-29.45%PremiumDec 20, 2024Expiry Date0.91Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.2549Delta0.0636Gamma1.21Leverage Ratio-0.1126Theta-0.0006Rho-0.31Eff Leverage0.0014Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet